#enov

Update: Enovis Announces Fourth Quarter and Full Year 2025 Results Enovis (NYSE: ENOV) reported fourth-quarter net sales of $576 million (Q4 growth 3% reported, 2% organic) and full-year 2025 net sales of $2.2 billion (+7% reported, +6% organic). Recon sales grew 10% for the year; P&R grew 4%.The company recorded a full-year net loss from continuing operations of $1,182 million including a $1,050 million non-cash goodwill impairment; adjusted EBITDA was $403 million. 2026 guidance: revenue $2.31–2.37 billion, adjusted EBITDA $425–435 million, adjusted EPS $3.52–3.73.

#ENOV Update: Enovis Announces Fourth Quarter and Full Year 2025 Results

www.stocktitan.net/news/ENOV/update-enovis-...

Enovis Announces Fourth Quarter and Full Year 2025 Results Enovis (NYSE: ENOV) reported fourth-quarter and full-year 2025 results on Feb 26, 2026. Full-year net sales were $2.2 billion, up 7% reported and 6% organic; fourth-quarter sales were $576 million, up 3% reported and 2% organic.The company recorded a full-year goodwill impairment of $1.05 billion (Q4 impairment of $501 million), resulting in net losses of $1,182 million for the year and $519 million in Q4. 2026 guidance: revenue ~$2.31-2.37 billion, adjusted EBITDA $425-435 million, and adjusted EPS $3.52-3.73.

#ENOV Enovis Announces Fourth Quarter and Full Year 2025 Results

www.stocktitan.net/news/ENOV/enovis-announc...

Enovis Announces Third Quarter 2025 Results Diversified growth platform delivers third-quarter sales growth of 9% on a reported basis, 7% organically Third-quarter Reconstructive sales grew 12% year-over-year on a reported basis, 9% organically October divestiture of Diabetic Footcare business unit from P&R for total proceeds of up to $60

#ENOV Enovis Announces Third Quarter 2025 Results

www.stocktitan.net/news/ENOV/enovis-announc...

Enovis completes sale of its Dr. Comfort Footcare Solutions business for proceeds of up to $60 million Enovis (NYSE: ENOV) completed the sale of its Dr. Comfort footcare diabetic shoe business to Promus Equity Partners for up to $60 million in cash, comprising an $45 million upfront payment and up to $15 million in milestone payments.The company said the divestiture sharpens focus on its Prevention & Recovery franchise, aims to expand margins, enhance profitability, and accelerate debt reduction. Enovis will discuss strategic details on its Q3 results call on Nov 6, 2025 at 8:30 am ET. Promus is a multi-family asset manager with approximately $2.7 billion under management. Citizens Capital Markets & Advisory and Tucker Ellis LLP advised Enovis.

#ENOV Enovis completes sale of its Dr. Comfort Footcare Solutions business for proceeds of up to $60 million

www.stocktitan.net/news/ENOV/enovis-complet...

Enovis Earnings Beat: Medical Tech Giant Raises 2025 Guidance as Reconstructive Sales Surge 11% Enovis boosts 2025 revenue outlook to $2.27B amid strong Q2 performance. Reconstructive segment leads growth with 11% jump. See full financial metrics.

#ENOV Enovis Announces Second Quarter 2025 Results

www.stocktitan.net/news/ENOV/enovis-announc...

Enovis Announces First Quarter 2025 Results Enovis Corporation (NYSE: ENOV) reported strong Q1 2025 financial results with net sales of $559 million, representing an 8% growth on a reported basis and 9% on a comparable basis. The company's Reconstructive segment showed impressive growth of 11% year-over-year, while P&R segment grew 5%. However, Enovis reported a net loss from continuing operations of $56 million (-$0.98 per share).The company achieved an adjusted EBITDA of $99 million (17.7% of sales), marking a 160 basis point improvement from the previous year. Enovis updated its 2025 guidance, raising revenue expectations to $2.22-2.25 billion but lowering adjusted EBITDA forecast to $385-395 million due to $20 million in tariff-related impact. The company also announced the appointment of Damien McDonald as CEO, effective May 12th, 2025.

#ENOV Enovis Announces First Quarter 2025 Results

www.stocktitan.net/news/ENOV/enovis-announc...

Enovis Announces Fourth Quarter and Full Year 2024 Results Enovis (NYSE: ENOV) reported strong Q4 2024 results with net sales of $561 million, up 23% year-over-year and 6% on comparable sales basis. The company's Reconstructive segment showed impressive growth of 59% reported (10% comparable), while Prevention & Recovery grew 2% reported (3% comparable).However, Enovis reported a significant Q4 net loss from continuing operations of $704 million, primarily due to a $645 million non-cash goodwill impairment charge. Q4 adjusted EBITDA reached $113 million (20% of sales), showing 210 basis points improvement year-over-year.For full-year 2024, net sales grew to $2.1 billion, up 23% reported and 6% comparable. The company provided 2025 guidance expecting revenue of $2.19-2.22 billion with 6-6.5% organic growth and adjusted EBITDA of $405-415 million. CEO Matt Trerotola announced his planned retirement, with a succession process underway.

#ENOV Enovis Announces Fourth Quarter and Full Year 2024 Results

www.stocktitan.net/news/ENOV/enovis-announc...

Enovis Announces CEO Retirement: Will the Leadership Change Impact Its MedTech Growth Strategy? Trerotola will serve as Executive Advisor for one year after successor appointment, ensuring continuity of Enovis' growth strategy and business culture.

#ENOV Enovis Announces Planned CEO Succession Process

www.stocktitan.net/news/ENOV/enovis-announc...

Construire un nuage de mots en direct à partir... des étiquettes des vêtements des élèves pour travailler l'inégale intégration des territoires dans la mondialisation ! #enov

#ENOV Enovis to Participate in Upcoming Investor Conferences

www.stocktitan.net/news/ENOV/enovis-to-part...